ERBB2 and breast cancer: A dose-escalation phase I/II trial has evaluated the tolerability and antitumor activity of epertinib combined with trastuzumab (arm A), with trastuzumab plus vinorelbine (arm B), or with trastuzumab plus capecitabine (arm C), in patients with HER2-positive BC, including with BM.